Jeffrey C Goh
机构: University of Queensland, Royal Brisbane & Women's Hospital
每年引用次数
引用次数
引用: 7,602
H-指数: 29
I10-指数 : 56
出版物: 178
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Amanda Pereira-Salgado , Angelyn Anton , Fanny Franchini , Robert K Mahar
Expert Review of Pharmacoeconomics & Outcomes Research 23 ( 2) 231 -239
2
2023
Session Chairs
David P Carbone , Joanna Dewar , Eryn Dow , Melissa Eastgate
Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
Angelyn Anton , Sruti Pillai , Marie Christine Semira , Shirley Wong
BJUI compass 3 ( 3) 205 -213
8
2022
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer–an Australian multi-centre observational study
Angelyn Anton , Shirley Wong , Julia Shapiro , Andrew Weickhardt
European Journal of Cancer 157 485 -492
8
2021
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis
Grace Chazan , Angelyn Anton , Shirley Wong , Julia Shapiro
Asia‐Pacific Journal of Clinical Oncology 18 ( 6) 642 -649
3
2022
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort
Michael Fernando , Angelyn Anton , Andrew Weickhardt , Arun A Azad
Journal of Geriatric Oncology 14 ( 8) 101621 -101621
2
2023
Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer
Richard Kelly , Angelyn Anton , Shirley Wong , Julia Shapiro
BJU international 128 18 -26
2
2021
Prostate‐specific membrane antigen positron emission tomography‐computed tomography use prior to systemic therapy in metastatic castration‐resistant prostate cancer.
Richard Kelly , Andrew Jensen , Nathasha Karunaratna , Shirley Wong
BJU international 131 ( 2)
1
2023
Examining Real-World Prescribing Practices for Novel Antiandrogens in Metastatic Castration Resistant Prostate Cancer
Owen Xie , Angelyn Anton , Ying Zhong , Shirley Wong
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 17 52 -52
2021
Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Nathasha Karunaratna , Andrew Jensen , Shirley Wong , Julia Shapiro
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 16 58 -58
2020
KEYNOTE-199: Phase 2 nonrandomized study of pembrolizumab in patients with PD-L1+ and PD-L1-metastatic castration-resistant prostate cancer
Johann de Bono , Josep Piulats , Marine Gross-Goupil , Jeffrey Goh
JOURNAL FOR IMMUNOTHERAPY OF CANCER 5
2017
Protocol: Pre-post feasibility trial of a telephone-delivered exercise intervention for patients during chemotherapy for recurrent ovarian cancer: the ECHO-R trial protocol
Sandra C Hayes , Rosalind R Spence , Monika Janda , Elizabeth Eakin
BMJ Open 14 ( 1)
2024
Pre-post feasibility trial of a telephone-delivered exercise intervention for patients during chemotherapy for recurrent ovarian cancer: the ECHO-R trial protocol
Sandra C Hayes , Rosalind R Spence , Monika Janda , Elizabeth Eakin
BMJ open 14 ( 1) e077158 -e077158
2024
TREATMENT SELECTION FOR FIRST-LINE METASTATIC RENAL CELL CARCINOMA (mRCC) IN AUSTRALIA: IMPACT OF NEW THERAPY OPTIONS
Andrew Schmidt , Arun Azad , Jeffrey Goh , Carole Harris
High‐dose chemotherapy for relapsed germ cell tumours: outcomes in low‐volume specialized centres
Elizabeth A Connolly , Andrew Weickhardt , Peter Grimison , Rebecca Asher
BJU international 130 5 -16
2
2022
Outcomes of high dose chemotherapy and stem cell transplantation for relapsed or refractory germ cell tumours from 1999-2019. An Australia and New Zealand (ANZ). registry-based study in collaboration with ABMTRR.
Liz Connolly , Andrew Weickhardt , Peter Grimison , Rebecca Asher
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 16 45 -45
2020
PARAGON-an ANZGOG phase 2 study of anastrazole in asymptomatic women with estrogen (ER)/progesterone (PR) positive ovarian cancer with a CA125 progression after first line treatment
Philip Beale , Rachel O’Connell , Katrin Sjoquist , Julie Martyn
Asia-Pacific Journal of Clinical Oncology 11 118 -118
1
2015
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer
Paul A Cohen , Penelope M Webb , Madeleine King , Andreas Obermair
International Journal of Gynecologic Cancer 32 ( 4)
6
2022
632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies
Rohit Joshi , Jeffrey Goh , Warren Joubert , Vineet Kwarta
Journal for ImmunoTherapy of Cancer 10 ( Suppl 2)
2022
O003/# 557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
Robert L Coleman , Amit Oza , Domenica Lorusso , Carol Aghajanian
International Journal of Gynecologic Cancer 32 ( Suppl 3)
19
2022